In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
CGD Policy Blogs
The UK example has some key lessons for all countries (including the UK itself) who are considering how to improve their current response, and how to “build back better” and prepare for future pandemics.
To attain and sustain universal health coverage, we must harness the power of healthcare innovation. But how can we do so when in many settings, these innovations do not align with local priorities?
In a context where global cooperation is needed perhaps more than ever before, how concerned should we be by efforts to “stockpile” potential treatments, and how can we encourage further cooperation? We look at the case of dexamethasone and remdesivir.
The authors look at the feasibility of the drug dexamethasone in low-income countries.
With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.
As Nigeria begins to relax stay-at-home orders, Nigerian policymakers, with support from its development partners, should adjust restrictions in line with local circumstances and re-focus on the essential building blocks of health system strengthening.
Flatten the Curve without Flattening the Economy: How to Stop COVID-19 from Causing Another Catastrophe for Health in Low- and Middle-Income Countries
Dozens of low- and middle-countries (LMICs) have now implemented stringent policies to slow the spread of COVID-19 in communities, in an effort to flattern the curve. Yet flattening the curve comes at a cost–it also flattens the economy
Following wide criticism of the way the government had been formulating and communicating its COVID-19 response, particularly on its scientific rationale, the UK government has initiated daily public briefings on the evolving crisis. Below we run through the UK government’s communications so far, and outline recommendations for the government to improve its communication ever further, by revamping its whole evidence-informed decision-making approach.
As countries strive to achieve the Sustainable Development Goals, including attaining and sustaining universal health coverage, decision-makers are increasingly using economic evaluation to drive macro policy choices and more granular technology-focused decisions. In a recent study, we discuss what cost-effective analysis (CEA) and benefit-cost analysis (BCA) have in common and where they differ, especially in relation to universal health coverage, in terms of the perspective of the analysis and how the methodologies relate (or not) to the viewpoints of healthcare policymakers and budget holders in low- and middle-income countries (LMICs).